ERNA — Ernexa Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 748592 ·
Last close
$2.49
Market Cap
$2.90M
52W High
$71.50
52W Low
$2.13
ADV30
71,036
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -4,104,000 | -4,009,000 | 6,315,000 | 5,028,000 | 3,115,000 |
| Mar 2026 | 0 | 0 | -3,546,000 | -5,506,000 | 10,543,000 | 9,177,000 | 3,684,000 |
| Dec 2025 | 0 | 0 | -2,094,000 | -1,502,000 | 5,834,000 | 1,884,000 | 3,433,000 |
| Sep 2025 | 0 | 0 | -1,993,000 | -1,240,000 | 6,172,000 | 3,047,000 | 2,602,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,216,000
Investing CF
$-39,000
Financing CF
$14,514,000
CapEx
$-17,000
Dividends Paid
$8,000
Buybacks
—
EPS Diluted TTM
$-83.71
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-251,142,000
Inventory
—
Receivables
$95,000
ST Investments
—
EBIT TTM
$-14,917,000
Pretax Income TTM
$-11,480,000
Interest Exp TTM
$3,483,000
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -9,319,000 | -14,084,000 | 5,834,000 | 3,433,000 | 2,401,000 | -7,017,000 |
| Dec 2024 | 582,000 | -17,250,000 | -44,539,000 | 5,269,000 | 3,568,000 | 1,701,000 | -15,836,000 |
| Dec 2023 | 68,000 | -20,675,000 | -21,668,000 | 49,132,000 | 46,899,000 | 2,233,000 | -20,408,000 |
| Dec 2022 | 0 | -26,947,000 | -24,579,000 | 22,279,000 | 10,172,000 | 12,107,000 | -20,976,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-11,388,000
OpCashFlow TTM
—
Assets (Latest)
$10,543,000
Forward EPS
$-9.60
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ONCO | Onconetix, Inc. | $2.87M | $0.65 | — |
| HCWB | HCW Biologics Inc. | $2.81M | $1.53 | — |
| MBIO | MUSTANG BIO, INC. | $2.81M | $0.42 | — |
| PRFX | PRF Technologies Ltd. | $3.00M | $0.86 | — |
| REVB | REVELATION BIOSCIENCES, INC. | $3.08M | $0.77 | — |
News headlines (Yahoo Finance, 1h cache)
Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
2026-10-06 12:55 · Yahoo
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
2026-10-01 13:20 · Yahoo
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
2026-09-30 12:32 · Yahoo
Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy
2026-09-29 13:15 · Yahoo
Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors
2026-09-17 12:42 · Yahoo
Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-14 13:05 · Yahoo
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
2026-08-27 13:01 · Yahoo
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
2026-07-24 13:20 · Yahoo
Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA)
2026-07-15 13:43 · Yahoo
Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
2026-06-25 13:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.